These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31425442)

  • 1. Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.
    Miroshnichenko II; Pozhidaev IV; Ivanova SA; Baymeeva NV
    Ther Drug Monit; 2020 Apr; 42(2):325-329. PubMed ID: 31425442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
    Darby JK; Pasta DJ; Wilson MG; Herbert J
    Clin Drug Investig; 2008; 28(9):553-64. PubMed ID: 18666802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.
    Polasek TM; Tucker GT; Sorich MJ; Wiese MD; Mohan T; Rostami-Hodjegan A; Korprasertthaworn P; Perera V; Rowland A
    Br J Clin Pharmacol; 2018 Mar; 84(3):462-476. PubMed ID: 29194718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
    Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
    PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism.
    Djordjevic N; Radmanovic B; Cukic J; Baskic D; Djukic-Dejanovic S; Milovanovic D; Aklillu E
    World J Biol Psychiatry; 2020 Jan; 21(1):29-52. PubMed ID: 30513034
    [No Abstract]   [Full Text] [Related]  

  • 9. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
    Rao ML; Hiemke C; Grasmäder K; Baumann P;
    Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.
    Xiao T; Wang Z; Li G; Huang S; Zhu X; Liu S; Li X; Hu J; Shang D; Wen Y
    Drug Des Devel Ther; 2021; 15():3411-3423. PubMed ID: 34376974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method.
    Albayrak M; Kadioglu Y; Yaman ME; Senol O; Oral E
    Biomed Chromatogr; 2019 Apr; 33(4):e4468. PubMed ID: 30549068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.
    Li A; Ji S; Yue W; Yan H; Dong F; Ruan C; Li W; Lu W; Zhang D; Wang C
    BMJ Open; 2018 Aug; 8(8):e020070. PubMed ID: 30121590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).
    Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H
    Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of olanzapine: Easy and reliable method for clinical correlation.
    Junutula SP; Dubasi SK; Reddy Padide SG; Miryala GK; Koppolu MS; Bandaru Sheshagiri SB; Eggadi V
    Indian J Pharmacol; 2021; 53(1):2-5. PubMed ID: 33975992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil.
    Ortner M; Stange M; Schneider H; Schröder C; Buerger K; Müller C; Müller-Sarnowski F; Diehl-Schmid J; Förstl H; Grimmer T; Steimer W
    Drug Des Devel Ther; 2020; 14():3251-3262. PubMed ID: 32848364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variables associated with high olanzapine dosing in a state hospital.
    Botts S; Littrell R; de Leon J
    J Clin Psychiatry; 2004 Aug; 65(8):1138-43. PubMed ID: 15323601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.